advertisement
Abstract #20077 Published in IGR 9-4
Effects of latanoprost, timolol and GLC756, a novel dopamine D2 agonist and D1 antagonist on LTC4 release after rat mast cell activation
Laengle UW; Markstein R; Pralet D; Seewald W; Roman DClinical and Experimental Ophthalmology 2007; 35: 645-650
PURPOSE: Mast cells participate in ocular allergic inflammation by releasing biologically active mediators. Leukotrienes are released from activated mast cells via an IgE-dependent mechanism, and play a crucial role in ocular allergic inflammation. In this study, the effect of three topical antiglaucoma drugs, that is, latanoprost, timolol and GLC756, a novel dopamine D2 agonist and D1 antagonist, on leukotriene C4 (LTC4) release after rat mast cell activation was examined. METHODS: A rat basophilic leukaemia RBL-2H3 mast cell line was activated via IgE/anti-IgE. Rat mast cells were incubated with latanoprost, timolol, or GLC756 at concentrations of 0.1, 1, 10 and 30 μM. LTC4 concentration in supernatant was assessed five hours post activation by EIA. RESULTS: Compared with controls, timolol showed no relevant effect on LTC4 release, five hours after mast cell activation. Latanoprost and GLC756, in contrast, revealed an inhibitory effect on LTC4 release, which was dose-related and statistically significant at the concentrations of 10 and 30 μM. CONCLUSION: The results of this study suggest that timolol has no significant influence on LTC4 release from activated mast cells. By contrast, latanoprost and GLC756 inhibited LTC4 release, suggesting a possible anti-inflammatory effect on ocular allergic inflammatory processes in topical glaucoma medication.
Dr. U.W. Laengle, Department of Toxicology/Pathology, Novartis Pharma AG, Basel, Switzerland
Classification:
11.14 Investigational drugs; pharmacological experiments (Part of: 11 Medical treatment)
11.4 Prostaglandins (Part of: 11 Medical treatment)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
